Skip to main content
. 2023 May 31;2023(5):CD014513. doi: 10.1002/14651858.CD014513

Hotu 2010.

Study characteristics
Methods A community‐based model of care improves blood pressure control and delays progression of proteinuria, left ventricular hypertrophy and diastolic dysfunction in Maori and Pacific patients with type 2 diabetes and chronic kidney disease: a randomized controlled trial
Patient RCT, conducted in hospital diabetes and renal clinics and primary care practices in 2 areas of Auckland, NZ, which provides comprehensive public health care, New Zealand
Two arms: 1. Usual care (control arm) and 2. Community/intervention care (intervention arm)
Participants Control arm N: 32
Intervention arm N: 33
Diabetes type: type 2
Mean age: NR ± NR
% Male: NR
Longest follow‐up: 12 months
Interventions Control arm:
1) Patient education
Intervention arm:
1) Case management
2) Team changes
3) Patient education
4) Financial incentives
Outcomes 1) HbA1c, mean % (SD)
Control arm: pre 8.5 (1.9), post 7.9 (1.7)
Intervention arm: pre 8.3 (1.6), post 8.0 (1.9)
2) SBP, mean mmHg (SD)
Control arm: pre 161.0 (20.0), post 149.0 (23.0)
Intervention arm: pre 161.0 (20.0), post 140.0 (19.0)
3) DBP, mean mmHg (SD)
Control arm: pre 85.0 (12.0), post 77.0 (12.0)
Intervention arm: pre 88.0 (9.0), post 78.0 (11.0)
Funding source This work was supported by funding from Auckland District Health Board and grants from the Health Research Council of New Zealand and Eli Lilly
Notes
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Does not describe process of randomisation.
Allocation concealment (selection bias) Unclear risk Does not describe process of allocation concealment.
Patient's baseline characteristics (selection bias) Low risk Quote: "there were no significant differences in any of the variables between the groups."
Patient's baseline outcomes (selection bias) Low risk Information not available.
Incomplete outcome data (attrition bias) High risk Per‐protocol analysis, baseline based on those randomised. They provide the numbers and reasons for loss to follow‐up, but reasons are not entirely clear for the control group.
Blinding of participants and personnel (performance bias) and of outcome assessors (detection bias) Low risk Primary: BP, using Omron.
Secondary: HbA1c, objective laboratory methods not described.
Blinding not described.
Selective reporting (reporting bias) Low risk Checked protocol and everything matches.
Risk of contamination (other bias) Low risk Information not available.
Other bias Low risk Information not available.